What Acorn Capital Advisors, LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2054410 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1.6M |
| −1.5% |
| $67M |
| 18.4% |
PBYIPuma Biotechnology, Inc. | 4.1M | ±0% | $41M | 11.3% |
CADLCandel Therapeutics, Inc. | 3.5M | ±0% | $36.5M | 10% |
TRVITrevi Therapeutics, Inc. | 2.1M | ±0% | $30.7M | 8.4% |
HELPHelus Pharma Inc. | 1.5M | ±0% | $18.9M | 5.2% |
JBIOJade Biosciences, Inc. | 986.8K | ±0% | $13.9M | 3.8% |
BCAXBicara Therapeutics Inc. | 668.4K | +3.9% | $12.4M | 3.4% |
VSTMVerastem, Inc. | 1.5M | ±0% | $11.8M | 3.2% |
OKUROnKure Therapeutics, Inc. | 2.8M | ±0% | $7.8M | 2.1% |
ENGNenGene Therapeutics Inc. | 3.8M | +199.8% | $7.6M | 2.1% |
ANTXAN2 Therapeutics, Inc. | 1.3M | New | $6.9M | 1.9% |
AURAAura Biosciences, Inc. | 1M | +10.4% | $6.4M | 1.8% |
TARAProtara Therapeutics, Inc. | 1.8M | ±0% | $5.3M | 1.5% |
ANNXAnnexon, Inc. | 1.1M | New | $4.8M | 1.3% |
LONALeonaBio, Inc. | 1.1M | +80.4% | $4.1M | 1.1% |
WHWKWhitehawk Therapeutics, Inc. | 932.1K | −18.2% | $3.5M | 1% |
QTTBQ32 Bio Inc. | 216.2K | ±0% | $1.8M | 0.5% |
KPTIKaryopharm Therapeutics Inc. | 1.2M | −19.5% | $1.5M | 0.4% |
JSPRJasper Therapeutics, Inc. | 1.4M | ±0% | $834.1K | 0.2% |
VYNEYarrow Bioscience, Inc. | 32K | +2,146.0% | $720.7K | 0.2% |
BCABBioAtla, Inc. | 108.1K | +0.0% | $140.6K | 0.1% |